YS Biopharma (YS) has released an update.
YS Biopharma, a global biopharmaceutical firm, has announced results from its extraordinary general meeting, which include the approval of a company name change to LakeShore Biopharma Co., Ltd, the appointment of five new directors, and the ratification of the 2024 Share Incentive Plan. These changes are being filed with the Cayman Islands Registrar of Companies and will be accompanied by a Nasdaq ticker symbol update for its shares and warrants.
For further insights into YS stock, check out TipRanks’ Stock Analysis page.
